Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014
Effect of omeprazole and AlOH/MgOH on riociguat absorption Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020
The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Spontaneous flow increase from implantable pump for intravenous treprostinil delivery Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016
Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015